MOR/CPR
[Create a profile and sign in to view pricing and add to cart]
- Description
- Ask a Question
Description
Description: MOR/CPR has been developed by growing the parent line, MOR, in increasing concentrations of cisplatin. The cells are cross-resistant to melphalan but show little or no cross-resistance to other platinum compounds. Cisplatin accumulation has been found to be reduced compared to the parent line.
Also Known As:
Species: Human
Tissue: Lung
Growth Properties: Aggregates in suspension
Morphology:
Growth Medium: RPMI 1640 + 2mM Glutamine + 1µg/ml cisplatin + 10% Foetal Bovine Serum (FBS).
Subculturing Procedure: Split subconfluent cultures (70-80%) 1:2 to 1:4 seeding at 2-4 x 10,000 cells/cm² using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C. It is recommended to culture the cells without drug after resuscitation until the first passage. These cells produce a lot of cell debris.
Release Conditions: No
Depositor: Dr P Twentyman, UKCCCR, Lincolns Inn Fields, London
Originator: Yes
References: Cancer Res 1992;52:5674
Hyperlink to ECACC Cell Line Data Sheet: 96042333
Ask a Question
Have a question about this product? Our technical team is here to help.
